The project seeks to develop a genetic test to determine the aggressiveness of thyroid cáncer
The prognosis test aims at predicting thyroid cancer’s biological behavior prior to treatment.
By adjusting treatment for the patient before the definitive surgical treatment, based on the true risk of progression of the disease. This allows the doctors to intensify the treatment in patients with an aggressive tumor and to be more conservative in cases of low aggressiveness.
Generating optimized treatments for the specific needs of the patient. Providing more efficient and cost effective medicine.
Hernán González, MD, PhD. He is currently Associate Professor of Surgery in the Department of Surgical Oncology at the Pontificia Universidad Católica de Chile. He completed his clinical fellowship in head and neck surgery at the MD Anderson Cancer Center. He maintains active clinical practice in the surgical treatment of patients with thyroid cancer with extensive experience in the management of advanced localized cancer and recurrent thyroid cancer.Read More
Dr. Hernán González has already developed the first test for thyroid nodules called Thyroidprint. This genetic test for diagnosing thyroid cancer has already been licensed to a Spin-off - called GeneproDX - which is close to being commercialized on the market.
This second test, currently under development at BMRC and focused on prognostic in thyroid cancer, could potentially follow the same commercial outflow through the GeneproDX Spin-off.